Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
暂无分享,去创建一个
C. Caldas | J. Abraham | H. Earl | D. Rea | D. Miles | M. Wilcox | A. Wardley | L. Hughes-Davies | J. Dunn | P. Hall | I. Macpherson | J. Mansi | L. Hiller | K. McAdam | D. Wheatley | D. Cameron | E. O’Riordan | S. Gasson
[1] C. Caldas,et al. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. , 2020, Health technology assessment.
[2] C. Tournigand,et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial , 2019, The Lancet.
[3] C. Caldas,et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial , 2019, The Lancet.
[4] Lauren L. Ritterhouse,et al. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] David A. Chambers,et al. Conceptualizing De-Implementation in Cancer Care Delivery. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Earl,et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] C. Caldas,et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. , 2018 .
[8] V. Georgoulias,et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] I. Graham,et al. “Entrenched practices and other biases”: unpacking the historical, economic, professional, and social resistance to de-implementation , 2015, Implementation Science.
[10] Jorma Isola,et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.
[11] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[12] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.